|Bid||66.25 x 2900|
|Ask||66.78 x 4000|
|Day's range||66.20 - 67.14|
|52-week range||53.63 - 71.70|
|Beta (5Y monthly)||0.12|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||1.45 (2.18%)|
|Ex-dividend date||11 Aug 2022|
|1y target est||73.38|
FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza as a combination therapy for patients with metastatic castration-resistant prostate cancer.
WILMINGTON, Del., August 16, 2022--AstraZeneca’s supplemental New Drug Application (sNDA) for LYNPARZA® (olaparib) in combination with abiraterone and prednisone or prednisolone has been accepted and granted Priority Review in the US for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC).
Gilead Sciences (NASDAQ: GILD) stock was off to a good start this week, rising by more than 5% on Monday against the modest (0.4%) gain of the S&P 500 index. The prominent pharmaceutical company had some good news to impart about an important cancer drug. Gilead announced that morning that its breast cancer treatment Trodelvy recorded "statistically significant and clinically meaningful" results in a phase 3 clinical trial.